Eyenovia Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.79
- Today's High:
- $1.87
- Open Price:
- $1.81
- 52W Low:
- $1.5
- 52W High:
- $5.85
- Prev. Close:
- $1.83
- Volume:
- 96309
Company Statistics
- Market Cap.:
- $109.07 million
- Book Value:
- 0.416
- Revenue TTM:
- $10 million
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $12.40 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -45.29%
- Return on Equity TTM:
- -115.82%
Company Profile
Eyenovia Inc had its IPO on 2018-01-25 under the ticker symbol EYEN.
The company operates in the Healthcare sector and Biotechnology industry. Eyenovia Inc has a staff strength of 41 employees.
Stock update
Shares of Eyenovia Inc opened at $1.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.79 - $1.87, and closed at $1.83.
This is a 0% increase from the previous day's closing price.
A total volume of 96,309 shares were traded at the close of the day’s session.
In the last one week, shares of Eyenovia Inc have slipped by -6.15%.
Eyenovia Inc's Key Ratios
Eyenovia Inc has a market cap of $109.07 million, indicating a price to book ratio of 3.228 and a price to sales ratio of 6.4156.
In the last 12-months Eyenovia Inc’s revenue was $10 million with a gross profit of $12.40 million and an EBITDA of $-24843496. The EBITDA ratio measures Eyenovia Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eyenovia Inc’s operating margin was 0% while its return on assets stood at -45.29% with a return of equity of -115.82%.
In Q1, Eyenovia Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 400%.
Eyenovia Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eyenovia Inc’s profitability.
Eyenovia Inc stock is trading at a EV to sales ratio of 5.5453 and a EV to EBITDA ratio of -3.0908. Its price to sales ratio in the trailing 12-months stood at 6.4156.
Eyenovia Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $29.31 million
- Total Liabilities
- $4.90 million
- Operating Cash Flow
- $-838052.00
- Capital Expenditure
- $920865
- Dividend Payout Ratio
- 0%
Eyenovia Inc ended 2024 with $29.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $29.31 million while shareholder equity stood at $15.81 million.
Eyenovia Inc ended 2024 with $0 in deferred long-term liabilities, $4.90 million in other current liabilities, 3799.00 in common stock, $-123969829.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.47 million and cash and short-term investments were $18.47 million. The company’s total short-term debt was $2,401,717 while long-term debt stood at $7.46 million.
Eyenovia Inc’s total current assets stands at $24.92 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $973677.00 compared to accounts payable of $1.40 million and inventory worth $0.
In 2024, Eyenovia Inc's operating cash flow was $-838052.00 while its capital expenditure stood at $920865.
Comparatively, Eyenovia Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.83
- 52-Week High
- $5.85
- 52-Week Low
- $1.5
- Analyst Target Price
- $13.5
Eyenovia Inc stock is currently trading at $1.83 per share. It touched a 52-week high of $5.85 and a 52-week low of $5.85. Analysts tracking the stock have a 12-month average target price of $13.5.
Its 50-day moving average was $2.09 and 200-day moving average was $2.68 The short ratio stood at 0.91 indicating a short percent outstanding of 0%.
Around 2243% of the company’s stock are held by insiders while 993.9% are held by institutions.
Frequently Asked Questions About Eyenovia Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company’s product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.